Icon

TALZENNA (nda211651)- (EQ 0.25MG BASE,EQ 1MG BASE,EQ 0.5MG BASE,EQ 0.75MG BASE,EQ 0.1MG BASE,EQ 0.35MG BASE)

TALAZOPARIB TOSYLATE PFIZER
EQ 0.25MG BASE,EQ 1MG BASE,EQ 0.5MG BASE,EQ 0.75MG BASE,EQ 0.1MG BASE,EQ 0.35MG BASE
No No
2031-Oct-20 2023-Oct-16
None None
None No
TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 0.25MG BASE ** ** - - -
EQ 1MG BASE ** ** - - -
EQ 0.5MG BASE ** ** - - -
EQ 0.75MG BASE ** ** - - -
EQ 0.1MG BASE ** ** - - -
EQ 0.35MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.